Navigation Links
Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial
Date:10/27/2015

SAN FRANCISCO, Oct. 27, 2015 /PRNewswire/ -- Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB-030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB-030 (previously SBCV-030), a locally applied, single-use treatment for the reduction of neointimal hyperplasia resulting from the vascular injury following percutaneous transluminal angioplasty (PTA).

This multicenter, parallel, blinded, randomized clinical trial is designed to compare the safety and efficacy of balloon angioplasty with or without the addition of SB-030 in peripheral artery disease (PAD) patients undergoing procedures for stenosis or occlusion within the superficial femoral artery (SFA). The trial will enroll approximately 66 patients at multiple sites in Australia and New Zealand.

"SB-030 is delivered locally at the site of injury during the end of the interventional procedure without a significant change to the standard-of-care," said Ken Horne, Chief Executive Officer of Symic Biomedical. "During surgical or interventional vascular procedures, the vulnerable lining of the vessel is injured, which leads to a local cascade of unwanted events, from initial inflammation to delayed neointimal hyperplasia (vessel scarring). SB-030 is designed specifically to prevent this cascade, and as a result, to reduce the risk of vessel restenosis caused by neointimal hyperplasia."

Dr. Andrew Holden, director of interventional services at Auckland City Hospital and Associate Professor of Radiology at Auckland University School of Medicine, New Zealand, said, "SB-030 represents a truly novel approach in the field of vascular intervention, particularly for patients being treated for PAD. We are excited to be a lead center in the evaluation of this treatment as part of the SHIELD Trial."

About SB-030

Symic is developing SB-030 (previously SBCV-030) as a locally applied, single-use treatment during vascular interventions. Engineered to mimic the healing and protective effects of naturally occurring proteoglycans, SB-030 reduces acute ECM-mediated inflammation and thus reduces the leading cause of restenosis, neointimal hyperplasia.

About Symic Biomedical

Symic Biomedical is a clinical-stage biotherapeutics platform company developing a pipeline of products targeting the extracellular matrix (ECM). Symic's proprietary compounds are inspired by proteoglycans, important structural and regulatory macromolecules native to the ECM, which is the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, play a critical role in healing following injury and in chronic diseases. SB-030 is Symic's lead compound under evaluation in the Phase 1/2 clinical study for vascular endothelial injury.

Symic Biomedical is based in San Francisco. For additional information, please visit the company's website at http://www.symic.bio.

Media Contacts

David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com


'/>"/>
SOURCE Symic Biomedical
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD
2. Symic Biomedical Announces Appointment of Barbara Yanni and Bill Newell as Independent Directors to its Board
3. G2 Intelligence and Arizona State Universitys International School of Biomedical Diagnostics Announce Diagnostic Research and Education Alliance
4. Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020
5. Mexico Biomedical Sensors Market Report 2015-2020
6. Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020
7. Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020
8. Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015
9. Journal of Biomedical Optics details ‘multiplicity of barriers’ to clinical acceptance of medical laser innovations
10. Journal’s ‘Light for Life’ section celebrates Year of Light, parallels Biomedical Optics conference
11. CIRTEC Medical Systems to support new UT Dallas-led Initiative to deliver biomedical technologies from laboratory bench to bedside more efficiently
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):